AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24534204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 24534204 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 18 μg
Number of subjects: 85
Study 22469638 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1.5 µg/kg)
Number of subjects: 15
Study 22469638 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (1.5 µg/kg)
Number of subjects: 15
Study 22469638 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fentanyl (0.75 µg/kg) and buprenorphine (0.75 µg/kg)
Number of subjects: 15
Study 22469638 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 15
Study 20681275 — intervention group
Group type: EXPERIMENTAL
Intervention: Shexiang Baoxin Pill (SXBXP) administered at 2 pills, three times a day for at least 6 months, in addition to conventional therapy.
Number of subjects: 200
Study 20681275 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (anti-platelet, blood lipid regulating, anti-ischemia) without SXBXP.
Number of subjects: 200
Study 20681275 — intervention group
Group type: EXPERIMENTAL
Intervention: Shexiang Baoxin Pill (SXBXP)
Number of subjects: 200
Study 17928942 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Hyperthermia (AH)
Number of subjects: 6
Study 16046473 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal Resistance Exercise (MRE) during LTBR
Number of subjects: 12
Study 16046473 — intervention group
Group type: COMPARATOR
Intervention: Long-term bedrest (LTBR) without exercise
Number of subjects: 12
Study 12455714 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors (ACEI) for four weeks
Number of subjects: 32
Study 12455714 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after two week wash out period)
Number of subjects: 32
Study 10600428 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized feedback system
Number of subjects: 19
Study 8530573 — intervention group
Group type: EXPERIMENTAL
Intervention: leuprolide depot (3.75 mg/month) plus conjugated estrogen (0.625 mg/day) and medroxyprogesterone acetate (10 mg; days 1‐12)
Number of subjects: 17
Study 8530573 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive pills (OCP) containing ethynodiol diacetate (1 mg) and ethinyl estradiol (35 micrograms)
Number of subjects: 17
Study 2009436 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 0
Study 6351529 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapride
Number of subjects: 13
Study 31036106 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve excision group (ilioinguinal neurectomy)
Number of subjects: 180
Study 31036106 — intervention group
Group type: COMPARATOR
Intervention: Nerve preservation group
Number of subjects: 180
Study 30037514 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL/kg of intravenous Lactated Ringer's solution (LR)
Number of subjects: 30
Study 30037514 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 30
Study 26690555 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (APAP; 1 g every 6 hours for seven days)
Number of subjects: 42
Study 26690555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 24612987 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg daily)
Number of subjects: 80
Study 24612987 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (160/800 mg daily)
Number of subjects: 80
Study 22065252 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular treatment (62 youths)
Number of subjects: 174
Study 22065252 — intervention group
Group type: COMPARATOR
Intervention: Standard manual treatment (59 youths)
Number of subjects: 174
Study 22065252 — intervention group
Group type: COMPARATOR
Intervention: Usual care (53 youths)
Number of subjects: 174
Study 19397178 — intervention group
Group type: EXPERIMENTAL
Intervention: RightStart program
Number of subjects: 0
Study 19397178 — intervention group
Group type: COMPARATOR
Intervention: Not in RightStart program (Control)
Number of subjects: 0
Study 17488375 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cyclosporine microemulsion (CsA‐ME, day 0)
Number of subjects: 203
Study 17488375 — intervention group
Group type: COMPARATOR
Intervention: Delayed cyclosporine microemulsion (CsA‐ME, day 6)
Number of subjects: 203
Study 17488375 — intervention group
Group type: EXPERIMENTAL
Intervention: Both early and delayed CsA‐ME groups
Number of subjects: 203
Study 16217327 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin B (5,000 IU diluted up to 20 ml)
Number of subjects: 20
Study 16217327 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 ml normal saline)
Number of subjects: 20
Study 11948071 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled study for treatment of asthma
Number of subjects: 0
Study 9585802 — intervention group
Group type: COMPARATOR
Intervention: Eprosartan 350 mg
Number of subjects: 31
Study 9585802 — intervention group
Group type: COMPARATOR
Intervention: Eprosartan 10 mg
Number of subjects: 31
Study 9585802 — intervention group
Group type: COMPARATOR
Intervention: Eprosartan 30 mg
Number of subjects: 31
Study 9585802 — intervention group
Group type: COMPARATOR
Intervention: Eprosartan 50 mg
Number of subjects: 31
Study 9585802 — intervention group
Group type: COMPARATOR
Intervention: Eprosartan 70 mg
Number of subjects: 31
Study 9585802 — intervention group
Group type: COMPARATOR
Intervention: Eprosartan 100 mg
Number of subjects: 31
Study 9585802 — intervention group
Group type: COMPARATOR
Intervention: Eprosartan 200 mg
Number of subjects: 31
Study 7857995 — intervention group
Group type: EXPERIMENTAL
Intervention: Active experimental drug
Number of subjects: 33
Study 7857995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 2530763 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 120
Study 2530763 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 120
Study 2530763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 1090297 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 17
Study 31941795 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC), 2,700 mg/d for adults; 30 mg/kg/d for pediatrics
Number of subjects: 33
Study 31941795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 31285161 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-Bang questionnaire
Number of subjects: 4118
Study 28662618 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face treatments (16 studies)
Number of subjects: 3879
Study 28662618 — intervention group
Group type: COMPARATOR
Intervention: Self-guided treatments (11 studies)
Number of subjects: 3879
Study 26593080 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen saturation targeting
Number of subjects: 0
Study 26593080 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 23222258 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated noninvasive ventilators
Number of subjects: 24
Study 23222258 — intervention group
Group type: COMPARATOR
Intervention: ICU ventilators
Number of subjects: 24
Study 23222258 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation sessions
Number of subjects: 24
Study 20845395 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine patch (9.5 mg/24 h)
Number of subjects: 0
Study 20845395 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine capsules (12 mg/day)
Number of subjects: 0
Study 20845395 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study 19334486 — intervention group
Group type: EXPERIMENTAL
Intervention: ronkoleukine therapy (0.1 mg submucously and 0.4 mg intravenously, 3 times with 72 hour intervals)
Number of subjects: 108
Study 19334486 — intervention group
Group type: COMPARATOR
Intervention: standard therapy (proton pump inhibitor and two antibiotics: amoxicillin and clarithromycin)
Number of subjects: 108
Study 16686568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI; 13.98 degrees C)
Number of subjects: 15
Study 16686568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice Water Immersion (IWI; 5.23 degrees C)
Number of subjects: 15
Study 16686568 — intervention group
Group type: COMPARATOR
Intervention: Mock Treatment (MT; 29.50 degrees C)
Number of subjects: 15
Study 15281968 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonosafe disposable tonometer head
Number of subjects: 69
Study 15281968 — intervention group
Group type: COMPARATOR
Intervention: Goldmann tonometer head
Number of subjects: 69
Study 15281968 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonosafe disposable tonometer head (subgroup analysis for IOP > 21 mmHg)
Number of subjects: 69
Study 15281968 — intervention group
Group type: COMPARATOR
Intervention: Goldmann tonometer head (subgroup analysis for IOP > 21 mmHg)
Number of subjects: 69
Study 15530582 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding promotion program
Number of subjects: 683
Study 15530582 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 683
Study 10357114 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium aurothiomalate (gold therapy)
Number of subjects: 36
Study 7594922 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidrug therapy regimen including rifampin, isoniazid, clofazimine, and dapsone for the first 3 months followed by clofazimine and dapsone until 84 months.
Number of subjects: 2
Study 7594922 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone alone for 60-80 months.
Number of subjects: 2
Study 2301439 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinyl glove use by hospital personnel for all body substance contact during the intervention period.
Number of subjects: 0
Study 2301439 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinyl glove use (intervention wards)
Number of subjects: 0
Study 2301439 — intervention group
Group type: COMPARATOR
Intervention: Control wards (no intervention)
Number of subjects: 0
Study 7395586 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertiveness training (twice a week for one hour for 10 weeks)
Number of subjects: 85
Study 30604381 — intervention group
Group type: EXPERIMENTAL
Intervention: GM1 acupoint injection (group A)
Number of subjects: 90
Study 30604381 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection (group B)
Number of subjects: 90
Study 30604381 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 90
Study 30604381 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (group D)
Number of subjects: 90
Study 27998971 — intervention group
Group type: EXPERIMENTAL
Intervention: S-288310 at 1 mg
Number of subjects: 38
Study 27998971 — intervention group
Group type: EXPERIMENTAL
Intervention: S-288310 at 2 mg
Number of subjects: 38
Study 27998971 — intervention group
Group type: EXPERIMENTAL
Intervention: S-288310
Number of subjects: 38
Study 27998971 — intervention group
Group type: EXPERIMENTAL
Intervention: S-288310 with CTL induction to both peptides
Number of subjects: 38
Study 27050101 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised decision aid with choice over the inclusion of up to 10 attributes
Number of subjects: 1970
Study 27050101 — intervention group
Group type: COMPARATOR
Intervention: Standard decision aid with a fixed set of five attributes
Number of subjects: 1970
Study 27050101 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised decision aid
Number of subjects: 1970
Study 27050101 — intervention group
Group type: COMPARATOR
Intervention: Standard decision aid
Number of subjects: 1970
Study 25090414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG), 10% Purified (Gamunex) administered monthly.
Number of subjects: 11
Study 25090414 — intervention group
Group type: COMPARATOR
Intervention: 0.1% albumin solution (placebo) administered monthly.
Number of subjects: 11
Study 22696005 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative liver volume regeneration index (RI(early)) at 7 days after surgery
Number of subjects: 91
Study 22696005 — intervention group
Group type: EXPERIMENTAL
Intervention: Total liver volume regeneration index (RI(total)) at 6 months after surgery
Number of subjects: 91
Study 22696005 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver remnant (LR) volume as a percentage of TLV at 7 days after surgery
Number of subjects: 91
Study 22696005 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver remnant (LR) volume as a percentage of TLV at 6 months after surgery
Number of subjects: 91
Study 18820883 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenum-preserving pancreatic head resection (DPPHR)
Number of subjects: 0
Study 18820883 — intervention group
Group type: COMPARATOR
Intervention: Pancreatoduodenectomy (PD)
Number of subjects: 0
Study 18820883 — intervention group
Group type: EXPERIMENTAL
Intervention: DPPHR techniques (Beger, Frey, Berne modifications)
Number of subjects: 0
Study 18820883 — intervention group
Group type: EXPERIMENTAL
Intervention: Berne modification of DPPHR
Number of subjects: 0
Study 17240130 — intervention group
Group type: EXPERIMENTAL
Intervention: Wormwood (3 x 500 mg/day)
Number of subjects: 40
Study 17240130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15665022 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg three times daily for 6 months
Number of subjects: 60
Study 12468310 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamb and rice diet
Number of subjects: 20
Study 12468310 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken and rice diet
Number of subjects: 20
Study 9658743 — intervention group
Group type: COMPARATOR
Intervention: Oral zinc tolerance test
Number of subjects: 382
Study 9658743 — intervention group
Group type: COMPARATOR
Intervention: Oral zinc dipicolinate tolerance test
Number of subjects: 382
Study 9658743 — intervention group
Group type: COMPARATOR
Intervention: Serum zinc concentration
Number of subjects: 382
Study 9658743 — intervention group
Group type: COMPARATOR
Intervention: Fecal chymotrypsin activity
Number of subjects: 382
Study 7660424 — intervention group
Group type: EXPERIMENTAL
Intervention: Lambdacyhalothrin-treated bed nets
Number of subjects: 5
Study 7660424 — intervention group
Group type: COMPARATOR
Intervention: Untreated nets
Number of subjects: 5
Study 7660424 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated nets
Number of subjects: 5
Study 2666046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Mandatory Ventilation (IMV)
Number of subjects: 200
Study 2666046 — intervention group
Group type: COMPARATOR
Intervention: T-piece
Number of subjects: 200
Study 2666046 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IMV and T-piece
Number of subjects: 200
Study 30898388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Acetaminophen (IA) 1000 mg every 6 hours
Number of subjects: 97
Study 30898388 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard pain control)
Number of subjects: 97
Study 30898388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Acetaminophen (IA)
Number of subjects: 97
Study 29145879 — intervention group
Group type: EXPERIMENTAL
Intervention: 2×10^6 per kilogram human umbilical-cord-derived MSCs (UC-MSCs) via peripheral vein injection preoperatively, and 5×10^6 cells via renal arterial injection during surgery, with standard induction therapy
Number of subjects: 100
Study 29145879 — intervention group
Group type: COMPARATOR
Intervention: Standard induction therapy
Number of subjects: 100
Study 29145879 — intervention group
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Number of subjects: 100
Study 24995962 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin flexible colonoscope (PCF‐PQ260)
Number of subjects: 84
Study 24995962 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscope (PCF‐Q260A)
Number of subjects: 84
Study 24995962 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study 24521323 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurobiology-based psychoeducation intervention (30-min lecture)
Number of subjects: 132
Study 24521323 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 132
Study 21518701 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin therapy
Number of subjects: 1
Study 21518701 — intervention group
Group type: COMPARATOR
Intervention: Healthy control
Number of subjects: 1
Study 20035579 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 1-3 mg/day
Number of subjects: 160
Study 20035579 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 4-6 mg/day
Number of subjects: 160
Study 20035579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 17696822 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (Medarex/Bristol‐Myers Squibb)
Number of subjects: 0
Study 17696822 — intervention group
Group type: EXPERIMENTAL
Intervention: CP‐675,206 (Pfizer/Abgenix, now Amgen)
Number of subjects: 0
Study 17696822 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 15361496 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow ramp rectal distension (40 ml/min)
Number of subjects: 14
Study 15361496 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid phasic rectal distension (900 ml/min, 10, 20, 30, and 40 mm Hg)
Number of subjects: 14
Study 11685356 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon autograft (PT)
Number of subjects: 65
Study 11685356 — intervention group
Group type: COMPARATOR
Intervention: Hamstring tendon autograft (HS)
Number of subjects: 65
Study 9725691 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin administration during surgery
Number of subjects: 9
Study 9725691 — intervention group
Group type: COMPARATOR
Intervention: Control day (no surgery)
Number of subjects: 9
Study 7991971 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback without electronic equipment
Number of subjects: 47
Study 7991971 — intervention group
Group type: COMPARATOR
Intervention: Control group (21 normal subjects)
Number of subjects: 47
Study 2728887 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone cement (methylmethacrylate) at operation
Number of subjects: 2
Study 2728887 — intervention group
Group type: COMPARATOR
Intervention: Plaster cast immobilization
Number of subjects: 2
Study 4804130 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers' class educational program
Number of subjects: 0
Study 4804130 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31277966 — intervention group
Group type: EXPERIMENTAL
Intervention: Bremelanotide 1.75 mg
Number of subjects: 0
Study 31277966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27655324 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Number of subjects: 353
Study 27655324 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen
Number of subjects: 353
Study 26067628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided pulsed radiofrequency (PRF) treatment and night splint
Number of subjects: 44
Study 26067628 — intervention group
Group type: COMPARATOR
Intervention: Night splint alone
Number of subjects: 44
Study 23541163 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Stress Reduction (MBSR)
Number of subjects: 93
Study 23541163 — intervention group
Group type: COMPARATOR
Intervention: Stress Management Education (SME)
Number of subjects: 93
Study 21806766 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician and patient education (PPE)
Number of subjects: 0
Study 21806766 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education only (PAE)
Number of subjects: 0
Study 21806766 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician education only (PHE)
Number of subjects: 0
Study 21806766 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study 18508277 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic saphenous vein harvesting (EVH)
Number of subjects: 132
Study 18508277 — intervention group
Group type: COMPARATOR
Intervention: Open venous harvesting (OVH)
Number of subjects: 132
Study 16101670 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 33
Study 16101670 — intervention group
Group type: EXPERIMENTAL
Intervention: Zone diet
Number of subjects: 33
Study 16101670 — intervention group
Group type: EXPERIMENTAL
Intervention: Zone diet with Omega-3
Number of subjects: 33
Study 16101670 — intervention group
Group type: COMPARATOR
Intervention: Control diet (placebo)
Number of subjects: 33
Study 12074361 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (n = 22), treadmill exercise program, 3 times per week for 12 weeks
Number of subjects: 42
Study 12074361 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20), no exercise
Number of subjects: 42
Study 12074361 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (n = 22)
Number of subjects: 42
Study 10434217 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightwand intubation (Trachlight, n = 25)
Number of subjects: 50
Study 10434217 — intervention group
Group type: COMPARATOR
Intervention: Direct-vision laryngoscopy (Laryngoscopy, n = 25)
Number of subjects: 50
Study 10434217 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 7582395 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled B-agonist
Number of subjects: 0
Study 7582395 — intervention group
Group type: EXPERIMENTAL
Intervention: New quality of life measuring instrument
Number of subjects: 0
Study 2350094 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine (90 mg)
Number of subjects: 0
Study 2350094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32573 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 0
Study 32573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31673875 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg/day orally on days 1-11, single oral dose of erdafitinib 4 mg on day 5
Number of subjects: 0